These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 18415895)
21. [Advances in the treatment of metastatic colorectal cancer with bevacizumab]. Longo F; Mansueto G Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449 [No Abstract] [Full Text] [Related]
22. [The efficacy of cetuximab for metastatic colorectal cancer]. Katsumoto Y; Aritake N; Endoh A Gan To Kagaku Ryoho; 2010 Nov; 37(12):2523-5. PubMed ID: 21224627 [TBL] [Abstract][Full Text] [Related]
23. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. Jackson C; Cunningham D Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913 [TBL] [Abstract][Full Text] [Related]
24. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. Moosmann N; Heinemann V Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070 [TBL] [Abstract][Full Text] [Related]
25. Biological agents versus chemotherapy in the treatment of colorectal cancer. Eng C; Shalan N Expert Opin Pharmacother; 2006 Jul; 7(10):1251-71. PubMed ID: 16805714 [TBL] [Abstract][Full Text] [Related]
26. Current therapies for advanced colorectal cancer. Aggarwal S; Chu E Oncology (Williston Park); 2005 Apr; 19(5):589-95. PubMed ID: 15945340 [TBL] [Abstract][Full Text] [Related]
27. Metastatic colorectal cancer: is there one standard approach? Saltz LB Oncology (Williston Park); 2005 Aug; 19(9):1147-54; discussion 1154, 1157-8, 1160. PubMed ID: 16255132 [TBL] [Abstract][Full Text] [Related]
28. Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. Morse MA IDrugs; 2005 Dec; 8(12):974-7. PubMed ID: 16320126 [No Abstract] [Full Text] [Related]
29. Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? Hoff PM; Ellis LM; Abbruzzese JL Oncology (Williston Park); 2004 May; 18(6):736-41; discussion 742, 745-6. PubMed ID: 15214593 [TBL] [Abstract][Full Text] [Related]
30. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Vokes EE; Chu E Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979 [TBL] [Abstract][Full Text] [Related]
34. [Novel molecular approaches in the therapy of advanced colorectal carcinoma]. Vanhoefer U Onkologie; 2003 Dec; 26 Suppl 7():70-4. PubMed ID: 14716146 [TBL] [Abstract][Full Text] [Related]
35. [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis]. Assenat E; Ychou M Bull Cancer; 2009 Dec; 96 Suppl():S41-6. PubMed ID: 20034869 [TBL] [Abstract][Full Text] [Related]
36. Targeted biotherapy in metastatic colorectal carcinoma: Current practice. Cacheux W; Le Tourneau C; Baranger B; Mignot L; Mariani P J Visc Surg; 2011 Feb; 148(1):12-8. PubMed ID: 21277276 [TBL] [Abstract][Full Text] [Related]
37. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? Fakih M Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698 [TBL] [Abstract][Full Text] [Related]
38. A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer. Rosati G; Aprile G; Cardellino GG; Avallone A J Geriatr Oncol; 2016 Mar; 7(2):134-41. PubMed ID: 26897044 [TBL] [Abstract][Full Text] [Related]
39. Adjuvant treatment of colon cancer: what is next? Van Loon K; Venook AP Curr Opin Oncol; 2011 Jul; 23(4):403-9. PubMed ID: 21537178 [TBL] [Abstract][Full Text] [Related]
40. [Molecular target therapy and chemotherapy for advanced colorectal cancer]. Nakashima K; Yamazaki K; Boku N Gan To Kagaku Ryoho; 2008 May; 35(5):725-30. PubMed ID: 18487907 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]